ArticleJournal of hepatocellular carcinoma2026
Comparative Performance of Stereotactic Body Radiotherapy and Lenvatinib in Unresectable Hepatocellular Carcinoma Complicated by Portal Vein Tumor Thrombosis: A Propensity Score-Matched Cohort Analysis.
Article in Journal of hepatocellular carcinoma, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To investigate whether adding stereotactic body radiotherapy (SBRT) to lenvatinib improves outcomes for patients with unresectable hepatocellular carcinoma (uHCC) and portal vein tumor thrombosis (PVTT). Methods: This retrospective cohort study enrolled 133 cases of uHCC with PVTT treated with either lenvatinib plus SBRT (n = 65) or lenvatinib alone (n = 68) between 2021 and 2023. To minimize baseline imbalances, 1:1 propensity score matching (PSM, caliper width, 0.02) was performed. The primary endpoints were overall survival (OS) and progression-free survival (PFS). Results: Across the full study population, patients receiving lenvatinib in combination with SBRT experienced significantly longer median OS relative to those who received lenvatinib alone (24.7 vs 16.4 months; HR=0.521, 95% CI: 0.338-0.802, p = 0.003). A similar advantage was observed for PFS (13.0 vs 8.6 months; HR=0.494, 95% CI: 0.335-0.728, p < 0.0001). These findings remained consistent after PSM, with hazard ratios of 0.589 for OS and 0.540 for PFS. The objective response rate was also substantially higher in the combination arm than in the monotherapy arm (55.4% vs 30.9%, p = 0.004). Subgroup analyses revealed that the survival advantage was confined to patients with Cheng's type I-II PVTT, whereas no significant benefit was observed in those with type III-IV disease. Furthermore, salvage hepatectomy was an independent protective factor for survival in 33 cases (24.8%), with a significantly higher conversion rate in the combined treatment group (30.8%). Both treatment groups had comparable and manageable safety profiles. Conclusion: Lenvatinib in combination with SBRT confers meaningful advantages in both survival and tumor response over lenvatinib monotherapy in individuals with uHCC and PVTT, particularly among those with Cheng's type I-II involvement. Moreover, this multimodal approach appears to be an effective strategy for achieving tumor downstaging and enabling subsequent salvage hepatectomy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.